We are building a deep pipeline of potentially differentiated therapies, with the goal of advancing care and outcomes for patients with diverse inflammatory diseases
- Preclinical
- Phase I
- Phase II
- Pivotal or Phase III*
Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)
- Preclin
- Ph 1
- Ph 2
- Ph 3
Atopic Dermatitis (AD)
Atopic Dermatitis (AD)
Asthma
Asthma
Small molecule targeting S1P1
(Th1 cell modulator)
- Preclin
- Ph 1
- Ph 2
- Ph 3
Ulcerative Colitis (UC)
Ulcerative Colitis (UC)
Crohn's Disease (CD) **
Crohn's Disease (CD) **
Peripherally restricted
H3 receptor antagonist
- Preclin
- Ph 1
- Ph 2
- Ph 3
Pruritus Associated with AD
Pruritus Assoc.
with AD
*The Company’s clinical trial in China of CBP-201 in patients with AD is included as the Company intends to submit a New Drug Application in China based on the results of this trial, pending pre-NDA discussions with the Chinese Center for Drug Evaluation of the National Medical Products Administration.
**Phase 2 CD trial ended early due to COVID-19-related enrollment challenges.
- Key:
- Ongoing
- Planned